Audited Financial Results for the 4th Quarter and Year ended 31.03.2026

Exceptional ItemRelated Party TransactionsResults View source PDF Explain this filing

VIMTALABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.3%Reaction day

₹510.70

prior close

₹529.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.6%-2.9% vs market

Healthcare Research Analytics & Technology peers, median of 5sector+2.6%-3.9% vs sector

On the reaction day the stock moved 2.9 pts less than Nifty Microcap 250 and 3.9 pts less than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+7.5

10m

+4.8

15m

+4.0

30m

+2.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.3+1.6-2.9+2.6-3.9

Next day

+0.5+1.5-1.0+2.4-1.9

-3.7+0.0-3.7+2.2-5.8

-8.3-3.0-5.3-0.9-7.4

-8.5-2.4-6.1-2.1-6.4

-10.3-2.1-8.2-3.1-7.2

-13.1-3.8-9.3+3.6-16.7

15d

-7.4-0.0-7.3-1.8-5.6

+2.4-1.0+3.4-0.8+3.2

+8.2+6.5+1.7-6.1+14.3

+27.7+10.2+17.6+1.5+26.3

UpDownMarket · Nifty Microcap 250Sector · Healthcare Research Analytics & Technology peers, median of 5Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Vimta Labs reported strong full-year results with total income growing 19.5% to ₹4,162.79 million from ₹3,482.22 million in FY25. Revenue from operations increased 18.4% to ₹4,072.90 million. Profit before tax rose 15% to ₹1,039.53 million while profit after tax from continuing operations grew 16% to ₹775.12 million. The company generated robust operating cash flow of ₹1,471.42 million, up from ₹940.54 million in the prior year. EPS from continuing operations stood at ₹17.20. The Board recommended dividend of ₹2 per share (100% payout on face value). The company also announced plans to set up a wholly-owned subsidiary in the USA and completed sale of its diagnostic business to Thyrocare in October 2024.

Likely market impact

Solid double-digit revenue and profit growth with clean audit opinion signals fundamental business strength. Strong cash generation reduces debt concerns while the USA expansion plan indicates growth ambition. Dividend payout provides near-term shareholder returns.